A clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of solid tumor cancers. The company is advancing miniprotein radioconjugate platforms designed to deliver therapeutic isotopes to cancer cells, with lead candidates in clinical trials for various cancer indications including urothelial, breast, lung, and prostate cancers.